KaloBios says it is appealing Nasdaq delisting


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (AP) — KaloBios, the biotech company formerly run by Martin Shkreli, says that it is appealing a decision by Nasdaq to delist the company from its stock market.

San Francisco-based KaloBios was notified last week that Nasdaq would move to delist the company's stock because of Shkreli's arrest and several other issues.

Shkreli was charged with securities fraud earlier this month. KaloBios subsequently fired him as CEO and he resigned from its board.

He became infamous earlier this year after another company he led, Turing Pharmaceuticals Inc., hiked the price of a life-saving drug by 5,000 percent. He resigned as CEO of Turing following his arrest.

KaloBios Pharmaceuticals Inc. said Tuesday that a hearing on its appeal to Nasdaq will take place in late February.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

The Associated Press
    KSL.com Beyond Series
    KSL.com Beyond Business

    KSL Weather Forecast

    KSL Weather Forecast
    Play button